TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 5nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 5nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 27nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 27nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 90nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 90nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 92nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 92nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 190nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
3D Structure (crystal)TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 190nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 324nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 324nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 700nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 700nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
